Martin and Harris Laboratories Limited · Health Care · Martin and Harris Laboratories Unlisted / Pre-IPO Share Price
As of 29 Oct 2026, the Martin and Harris Laboratories Limited unlisted share price is ₹875 per share. Implied valuation: ₹350 Cr. Martin and Harris Laboratories Limited is an unlisted / pre-IPO company — not listed on NSE or BSE. Minimum investment: ₹50,000. ISIN: INE03VV01015.
▼ ₹1,035 (−53.63%) over all time
Key figures for Martin and Harris Laboratories Limited
Martin & Harris Laboratories Limited is a pharmaceutical company engaged in contract manufacturing and branded formulations, historically associated with the Apeejay Stya group. The company’s portfolio spans therapeutic segments including anti-infectives, pain management, respiratory and gastro-intestinal. Facilities and quality systems align with Indian regulatory standards, and the company collaborates with distribution partners for domestic reach. Corporate materials trace legacy brands and manufacturing capabilities supporting scale, compliance and patient accessibility across selected markets.
| Particulars | FY21 | FY22 | FY23 | FY24 | FY25 LATEST |
|---|---|---|---|---|---|
| Revenue | 168 | 186 | 205 | 146 | 107.4▼26% |
| EBITDA | 60 | 70 | 72 | 26 | 8.4▼68% |
| OPM (%) | 35.71% | 37.63% | 35.12% | 17.81% | 7.82%▼56% |
| PBT | 69 | 93 | 92 | 55 | 83▲51% |
| PAT | 52 | 70 | 68 | 40 | 66.4▲66% |
| EPS (₹) | ₹133.33 | ₹175.44 | ₹170.43 | ₹100.25 | ₹166.42▲66% |
Figures in ₹ Crore unless marked ₹ (per share) or %. Source: company filings via unlistedzone.
Martin and Harris Laboratories shares are unlisted, so they are bought off-market through a SEBI-registered intermediary rather than on the NSE or BSE. With Safal Capital the process is simple:
No. Martin and Harris Laboratories is currently an unlisted / pre-IPO company, so its shares are not traded on the NSE or BSE and there is no live “Martin and Harris Laboratoriesshare price NSE”. They are transacted off-market between buyers and sellers through SEBI-registered intermediaries such as Safal Capital.
Martin and Harris Laboratories has not announced a confirmed IPO date. Investors buy unlisted shares ahead of a potential listing for pre-IPO upside, but a listing is never guaranteed and timelines can change. The ISIN for Martin and Harris Laboratories is INE03VV01015. Contact our desk for the latest status and a live quote before you invest.
Martin and Harris Laboratories Limited is an unlisted company operating in the Health Care sector (Pharmaceuticals). Martin & Harris Laboratories Limited is a pharmaceutical company engaged in contract manufacturing and branded formulations, historically associated with the Apeejay Stya group. The company’s portfolio spans therapeutic segments including anti-infectives, pain management, respiratory and gastro-inte…
The current unlisted market price is ₹886.05 per share with a market capitalisation of approximately ₹358 crore. The company is currently unlisted and investors should factor in illiquidity risk and longer holding horizons. Investors are advised to review the full financial data and consult an advisor before investing.
Leave your name and mobile, our unlisted shares desk will call you back with live pricing and availability.
Latest source-linked updates that may be relevant to this company.
Restaurant Brands Asia Q2 FY27 slides: India drives 281% EBITDA surge By Investing.com Investing.com India
Stock markets witness bull-run, Sensex gains over 900 points The Statesman
Infobay AI Raises Again: Kacholia, Bajaj Finance on Board UnlistedZone
As of 29 Oct 2026, the Martin and Harris Laboratories unlisted (pre-IPO) share price is ₹875 per share on Safal Capital. Unlisted share prices move with demand, supply and deal size, so contact our desk for a live, deal-specific quote before you transact.
At the unlisted share price of ₹875, Martin and Harris Laboratories's implied market valuation is about ₹350 Cr (share price × total shares outstanding). This is an indicative, market-implied figure that moves with the unlisted price — not an official company valuation.
You buy Martin and Harris Laboratories unlisted shares off-market through a SEBI-registered intermediary. With Safal Capital: (1) share your requirement and quantity, (2) we confirm the live price and availability, (3) you complete KYC, (4) transfer funds, and (5) the shares are credited to your demat account, usually within T+1 to T+2 working days.
No. Martin and Harris Laboratories is currently an unlisted / pre-IPO company, so its shares are not traded on the NSE or BSE. They are transacted off-market between buyers and sellers through SEBI-registered intermediaries such as Safal Capital.
Unlisted shares like Martin and Harris Laboratories are high-growth but illiquid. Balance them with these — all with the same SEBI-registered team.
Martin and Harris Laboratories has not announced a confirmed IPO date. Unlisted shares are often bought before a potential listing in the hope of pre-IPO gains, but a listing is never guaranteed and timelines can change. Speak to our advisors for the latest status on Martin and Harris Laboratories.
The ISIN for Martin and Harris Laboratories unlisted shares is INE03VV01015. You will need this ISIN when the shares are credited to your demat account.
Martin and Harris Laboratories unlisted shares have a face value of ₹10 and a typical minimum lot of 100 shares. Minimum quantities can vary with availability and deal size — our desk will confirm the current lot before you invest.
Unlisted share prices are not set by an exchange. The Martin and Harris Laboratories price reflects recent off-market deals, buyer/seller demand, the company's financials and expectations around a future IPO. Because it is over-the-counter, always confirm a live quote before transacting.
Unlisted shares like Martin and Harris Laboratories can offer pre-IPO upside but carry higher risk and lower liquidity than listed stocks, and there is no guaranteed exit. Invest only after reviewing the company's fundamentals and your risk profile — Safal Capital's SEBI-registered advisors can help you assess Martin and Harris Laboratories.
